Top Markets
#1 Black Phoenix Black Phoenix +828.60%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.27%
#3 Beam Beam +25.92%
#4 Not in Employment, Education, or Training Not in Employment, Education, or Training +23.39%
#5 SAFEcoin SAFEcoin +20.79%
#6 Magma Finance Magma Finance +19.47%
#7 pipedog pipedog +19.13%
#8 Bless Bless +16.57%
#9 PondCoin PondCoin +16.30%
#10 THORChain THORChain +15.72%
Coin of the day
Black Phoenix Black Phoenix
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
CymaBay Therapeutics, Inc. CymaBay Therapeutics, Inc.

CymaBay Therapeutics, Inc.

CBAY
Peringkat dalam Saham #6078
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical... CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with type 1 diabetes. CymaBay maintains strategic partnerships, including a licensing arrangement with ABW Cyclops SPV LP to aid the development of seladelpar for PBC. They also possess a global license from Janssen Pharmaceuticals, Inc. to research, develop, and bring to market compounds active against an undisclosed metabolic disease target. Established in 1988 and formerly known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.
Harga Saham
$32.48
Terakhir disinkronkan: 2024-03-25
Kapitalisasi Pasar
$2.24B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan CymaBay Therapeutics, Inc. (CBAY)

Kategori

Healthcare
Rasio P/E untuk CymaBay Therapeutics, Inc. (CBAY)
Rasio P/E per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari CymaBay Therapeutics, Inc., rasio P/E saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki rasio P/E sebesar 0.
Riwayat rasio P/E untuk CymaBay Therapeutics, Inc. dari 2026 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.